— Know what they know.
Not Investment Advice

CGTX NASDAQ

Cognition Therapeutics, Inc.
1W: -1.2% 1M: -11.9% 3M: -13.5% YTD: -37.1% 1Y: -38.7% 3Y: -31.0%
$0.93
+0.03 (+3.80%)
 
Weekly Expected Move ±6.0%
$1 $1 $1 $1 $1
NASDAQ · Healthcare · Biotechnology · Tech Score Strong Sell · Power 29 · $82.8M mcap · 82M float · 1.34% daily turnover · Short 49% of daily vol

Balance Sheet Trends

Total Assets
$48M +60.1% ▲
5Y CAGR: +46.7%
Total Liabilities
$14M +22.9% ▲
5Y CAGR: -28.5%
Shareholders Equity
$34M +82.8% ▲
Cash & Investments
$37M +47.2% ▲
5Y CAGR: +48.0%
Total Debt
$638K -21.6% ▼
5Y CAGR: -45.2%
Net Debt
-$36M -49.5% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$55M$42M$30M$25M$37M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$55M$42M$30M$25M$37M
Net Receivables$2M$4M$1M$3M$10M
Inventory$0$0$0$0$0
Other Current Assets$11K$0$3M$0$1M
Total Current Assets$59M$48M$34M$30M$48M
Property, Plant & Equip.$145K$1M$941K$679K$399K
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$0$2M$0$0$0
Total Non-Current Assets$145K$3M$941K$679K$399K
Total Assets$59M$50M$35M$30M$48M
— Liabilities —
Accounts Payable$4M$3M$4M$2M$1M
Short-Term Debt$0$634K$544K$279K$443K
Deferred Revenue$753K$2M$2M$1M$367K
Other Current Liabilities$2M$870K$1M$2M$12M
Total Current Liabilities$8M$8M$10M$11M$14M
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$0$695K$0$0$0
Total Non-Current Liabilities$0$2M$520K$342K$195K
Total Liabilities$8M$10M$11M$11M$14M
— Equity —
Common Stock$22K$29K$32K$60K$90K
Retained Earnings-$94M-$115M-$141M-$175M-$199M
Accumulated OCI-$198K-$199K-$195K$0$0
Total Stockholders Equity$51M$40M$24M$19M$34M
Total Liabilities & Equity$59M$50M$35M$30M$48M
— Key Metrics —
Total Debt$0$1M$1M$814K$638K
Net Debt-$55M-$40M-$29M-$24M-$36M
Total Investments$0$0$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms